Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
About this item
Full title
Author / Creator
TRANSFORMS Study Group , Cohen, Jeffrey A , Barkhof, Frederik , Comi, Giancarlo , Hartung, Hans-Peter , Khatri, Bhupendra O , Montalban, Xavier , Pelletier, Jean , Capra, Ruggero , Gallo, Paolo , Izquierdo, Guillermo , Tiel-Wilck, Klaus , de Vera, Ana , Jin, James , Stites, Tracy , Wu, Stacy , Aradhye, Shreeram and Kappos, Ludwig
Publisher
Waltham, MA: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
Waltham, MA: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
In this 12-month trial involving patients with relapsing–remitting multiple sclerosis, oral fingolimod was more effective than intramuscular interferon beta-1a in reducing relapse rates. Adverse events associated with fingolimod included herpesvirus infections (two fatal infections), atrioventricular block, macular edema, skin cancer, and liver-enz...
Alternative Titles
Full title
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_hal_primary_oai_HAL_hal_00617750v1
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_hal_primary_oai_HAL_hal_00617750v1
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa0907839
